{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:08:38Z","timestamp":1790215718013,"version":"4.1.0"},"reference-count":47,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Deutsche Forschungsgemeinschaft (DFG)","award":["SFB 1039"],"award-info":[{"award-number":["SFB 1039"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Cutaneous T cell lymphomas (CTCLs) represent a heterogeneous group of T cell lymphomas that primarily affect the skin. The most frequent forms of CTCL are mycosis fungoides and S\u00e9zary syndrome. Both are characterized by frequent recurrence, developing chronic conditions and high mortality with a lack of a curative treatment. In this study, we evaluated the effect of short-chain, cell-permeable C6 Ceramide (C6Cer) on CTCL cell lines and keratinocytes. C6Cer significantly reduced cell viability of CTCL cell lines and induced cell death via apoptosis and necrosis. In contrast, primary human keratinocytes and HaCaT keratinocytes were less affected by C6Cer. Both keratinocyte cell lines showed higher expressions of ceramide catabolizing enzymes and HaCaT keratinocytes were able to metabolize C6Cer faster and more efficiently than CTCL cell lines, which might explain the observed protective effects. Along with other existing skin-directed therapies, C6Cer could be a novel well-tolerated drug for the topical treatment of CTCL.<\/jats:p>","DOI":"10.3390\/cancers13020270","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T11:52:32Z","timestamp":1610538752000},"page":"270","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["C6 Ceramide (d18:1\/6:0) as a Novel Treatment of Cutaneous T Cell Lymphoma"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6854-1917","authenticated-orcid":false,"given":"Raphael","family":"Wilhelm","sequence":"first","affiliation":[{"name":"Department of General Pharmacology and Toxicology, Goethe University Hospital and Goethe University Frankfurt, 60590 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0156-8840","authenticated-orcid":false,"given":"Timon","family":"Eckes","sequence":"additional","affiliation":[{"name":"Department of General Pharmacology and Toxicology, Goethe University Hospital and Goethe University Frankfurt, 60590 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergely","family":"Imre","sequence":"additional","affiliation":[{"name":"Department of General Pharmacology and Toxicology, Goethe University Hospital and Goethe University Frankfurt, 60590 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kippenberger","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venerology and Allergology, Goethe University Hospital, 60590 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5630-587X","authenticated-orcid":false,"given":"Markus","family":"Meissner","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venerology and Allergology, Goethe University Hospital, 60590 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4153-3669","authenticated-orcid":false,"given":"Dominique","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Goethe University Hospital and Goethe University Frankfurt, 60590 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Trautmann","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Goethe University Hospital and Goethe University Frankfurt, 60590 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0305-0850","authenticated-orcid":false,"given":"Jean-Philippe","family":"Merlio","sequence":"additional","affiliation":[{"name":"Cutaneous Lymphoma Oncogenesis Team, INSERM U1053 Bordeaux Research in Translational Oncology, Bordeaux University, 33076 Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Chevret","sequence":"additional","affiliation":[{"name":"Cutaneous Lymphoma Oncogenesis Team, INSERM U1053 Bordeaux Research in Translational Oncology, Bordeaux University, 33076 Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Kaufmann","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venerology and Allergology, Goethe University Hospital, 60590 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Pfeilschifter","sequence":"additional","affiliation":[{"name":"Department of General Pharmacology and Toxicology, Goethe University Hospital and Goethe University Frankfurt, 60590 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Koch","sequence":"additional","affiliation":[{"name":"Department of General Pharmacology and Toxicology, Goethe University Hospital and Goethe University Frankfurt, 60590 Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"J\u00e4ger","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venerology and Allergology, Goethe University Hospital, 60590 Frankfurt am Main, Germany"},{"name":"Hautklinik, St\u00e4dtisches Klinikum Karlsruhe, Akademisches Lehrkrankenhaus der Universit\u00e4t Freiburg, 76133 Karlsruhe, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000018423","article-title":"Mycosis Fungoides: Review of Epidemiological Observations","volume":"201","author":"Vila","year":"2000","journal-title":"Dermatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjd.17240","article-title":"British Association of Dermatologists and U.K. Cutaneous Lymphoma Group Guidelines for the Management of Primary Cutaneous Lymphomas 2018","volume":"180","author":"Gilson","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC Classification for Cutaneous Lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Willemze, R., Cerroni, L., and Kempf, W. (2019). Erratum: The 2018 Update of the WHO-EORTC Classification for Primary Cutaneous Lymphomas (Blood (2019) 133: 16 (1703\u20131714) DOI: 10.1182\/Blood-2018-11-881268). Blood, 1112.","DOI":"10.1182\/blood-2018-11-881268"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.cll.2017.06.006","article-title":"Cutaneous T-Cell Lymphoma","volume":"37","author":"Pulitzer","year":"2017","journal-title":"Clin. Lab. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.12788\/j.sder.2018.002","article-title":"Mycosis Fungoides-Clinical and Histopathologic Features, Differential Diagnosis, and Treatment","volume":"37","author":"Cerroni","year":"2018","journal-title":"Semin. Cutan. Med. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2009-11-251926","article-title":"S\u00e9zary Syndrome and Mycosis Fungoides Arise from Distinct T-Cell Subsets: A Biologic Rationale for Their Distinct Clinical Behaviors","volume":"116","author":"Campbell","year":"2010","journal-title":"Blood"},{"key":"ref_8","first-page":"112","article-title":"S2k Guidelines\u2014Cutaneous Lymphomas Update 2016\u2014Part 2: Treatment and Follow-up (ICD10 C82\u2014C86)","volume":"16","author":"Dippel","year":"2018","journal-title":"JDDG J. Ger. Soc. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s00105-017-4021-5","article-title":"Treatment of Mycosis Fungoides and S\u00e9zary Syndrome","volume":"68","author":"Nicolay","year":"2017","journal-title":"Hautarzt"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/ajh.25577","article-title":"Mycosis Fungoides and S\u00e9zary Syndrome: 2019 Update on Diagnosis, Risk-Stratification, and Management","volume":"94","author":"Hristov","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Valipour, A., J\u00e4ger, M., Wu, P., Schmitt, J., Bunch, C., and Weberschock, T. (2020). Interventions for Mycosis Fungoides. Cochrane Database Syst. Rev., 7.","DOI":"10.1002\/14651858.CD008946.pub3"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","article-title":"Primary Cutaneous Lymphomas: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"29","author":"Willemze","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus Vorinostat in Previously Treated Cutaneous T-Cell Lymphoma (MAVORIC): An International, Open-Label, Randomised, Controlled Phase 3 Trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab Vedotin or Physician\u2019s Choice in CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA): An International, Open-Label, Randomised, Phase 3, Multicentre Trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/ijd.14132","article-title":"Health-Related Quality of Life in Patients with Cutaneous T-Cell Lymphoma?","volume":"57","author":"Holahan","year":"2018","journal-title":"Int. J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrc.2017.96","article-title":"Sphingolipid Metabolism in Cancer Signalling and Therapy","volume":"18","author":"Ogretmen","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1006\/taap.1996.8029","article-title":"Sphingolipids\u2014The Enigmatic Lipid Class: Biochemistry, Physiology and Pathophysiology","volume":"142","author":"Merrill","year":"1997","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1016\/S0021-9258(17)41834-5","article-title":"The Sphingomyelin Cycle and the Second Messenger Function of Ceramide","volume":"269","author":"Hannun","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1242\/jcs.00153","article-title":"Caspase-Dependent Initiation of Apoptosis and Necrosis by the Fas Receptor in Lymphoid Cells: Onset of Necrosis Is Associated with Delayed Ceramide Increase","volume":"115","author":"Hetz","year":"2002","journal-title":"J. Cell Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"20313","DOI":"10.1074\/jbc.274.29.20313","article-title":"Long Chain Ceramides Activate Protein Phosphatase-1 and Protein Phosphatase-2A. Activation Is Stereospecific and Regulated by Phosphatidic Acid","volume":"274","author":"Chalfant","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"15523","DOI":"10.1016\/S0021-9258(18)82288-8","article-title":"Ceramide Activates Heterotrimeric Protein Phosphatase 2A","volume":"268","author":"Dobrowsky","year":"1993","journal-title":"J. Biol. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"16568","DOI":"10.1074\/jbc.273.26.16568","article-title":"Inhibition of Akt Kinase by Cell-Permeable Ceramide and Its Implications for Ceramide-Induced Apoptosis","volume":"273","author":"Zhou","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_23","first-page":"108","article-title":"Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer","volume":"20","author":"Iskender","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1074\/jbc.273.5.2910","article-title":"Sphingosine 1-Phosphate Inhibits Activation of Caspases That Cleave Poly(ADP-Ribose) Polymerase and Lamins during Fas- and Ceramide-Mediated Apoptosis in Jurkat T Lymphocytes","volume":"273","author":"Cuvillier","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/S0006-2952(03)00125-4","article-title":"Mechanisms Involved in Exogenous C2- and C6-Ceramide-Induced Cancer Cell Toxicity","volume":"65","author":"Fillet","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.freeradbiomed.2007.12.017","article-title":"Ceramide-Induced Formation of ROS and ATP Depletion Trigger Necrosis in Lymphoid Cells","volume":"44","author":"Villena","year":"2008","journal-title":"Free Radic. Biol. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.yexcr.2014.12.017","article-title":"C6 Ceramide Dramatically Enhances Docetaxel-Induced Growth Inhibition and Apoptosis in Cultured Breast Cancer Cells: A Mechanism Study","volume":"332","author":"Yang","year":"2015","journal-title":"Exp. Cell Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.bbrc.2016.08.121","article-title":"Short-Chain C6 Ceramide Sensitizes AT406-Induced Anti-Pancreatic Cancer Cell Activity","volume":"479","author":"Zhao","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1053\/j.gastro.2017.10.050","article-title":"Nanoliposome C6-Ceramide Increases the Anti-Tumor Immune Response and Slows Growth of Liver Tumors in Mice","volume":"154","author":"Li","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/gut.2010.216671","article-title":"Nanoliposomal Ceramide Prevents in Vivo Growth of Hepatocellular Carcinoma","volume":"60","author":"Tagaram","year":"2011","journal-title":"Gut"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1023\/A:1024409123726","article-title":"A Phase II Study of Topical Ceramides for Cutaneous Breast Cancer","volume":"80","author":"Jatoi","year":"2003","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.bbamem.2015.11.019","article-title":"Ceramides with a Pentadecasphingosine Chain and Short Acyls Have Strong Permeabilization Effects on Skin and Model Lipid Membranes","volume":"1858","year":"2016","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/0092-8674(95)90541-3","article-title":"Yama\/CPP32\u03b2, a Mammalian Homolog of CED-3, Is a CrmA-Inhibitable Protease That Cleaves the Death Substrate Poly(ADP-Ribose) Polymerase","volume":"81","author":"Tewari","year":"1995","journal-title":"Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"558","DOI":"10.4161\/auto.5.4.8390","article-title":"Ceramide-Induced Autophagy: To Junk or to Protect Cells?","volume":"5","author":"Pattingre","year":"2009","journal-title":"Autophagy"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Ravanan, P., Srikumar, I.F., and Talwar, P. (2017). Autophagy: The Spotlight for Cellular Stress Responses. Life Sci., 53\u201367.","DOI":"10.1016\/j.lfs.2017.08.029"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.bcp.2010.04.001","article-title":"Metabolism of Short-Chain Ceramide by Human Cancer Cells\u2014Implications for Therapeutic Approaches","volume":"80","author":"Chapman","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1126\/science.4035344","article-title":"Defining Lipid Transport Pathways in Animal Cells","volume":"229","author":"Pagano","year":"1985","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.2174\/0929867054864822","article-title":"Amphiphilic Transdermal Permeation Enhancers: Structure-Activity Relationships","volume":"12","author":"Vavrova","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2147\/DDDT.S137106","article-title":"Clinical Potential of Mechlorethamine Gel for the Topical Treatment of Mycosis Fungoides-Type Cutaneous t-Cell Lymphoma: A Review on Current Efficacy and Safety Data","volume":"12","author":"Liner","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2147\/CMAR.S138661","article-title":"Management of Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma (MF-CTCL): Focus on Chlormethine Gel","volume":"11","author":"Denis","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4103\/0378-6323.178903","article-title":"Topical Corticosteroids in Dermatology","volume":"82","author":"Mehta","year":"2016","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1111\/ajd.12762","article-title":"Comparative Safety and Efficacy of Topical Mometasone Furoate with Other Topical Corticosteroids","volume":"59","author":"Spada","year":"2018","journal-title":"Australas. J. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4103\/2229-5178.142483","article-title":"Side-Effects of Topical Steroids: A Long Overdue Revisit","volume":"5","author":"Coondoo","year":"2014","journal-title":"Indian Dermatol. Online J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2005.01.010","article-title":"Adverse Effects of Topical Glucocorticosteroids","volume":"54","author":"Hengge","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.biochi.2013.07.027","article-title":"Ceramide and the Mitochondrial Respiratory Chain","volume":"100","author":"Saada","year":"2014","journal-title":"Biochimie"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"158821","DOI":"10.1016\/j.bbalip.2020.158821","article-title":"Consistent Alteration of Chain Length-Specific Ceramides in Human and Mouse Fibrotic Kidneys","volume":"1866","author":"Eckes","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"120593","DOI":"10.1016\/j.talanta.2019.120593","article-title":"Implementation of Lipidomics in Clinical Routine: Can Fluoride\/Citrate Blood Sampling Tubes Improve Preanalytical Stability?","volume":"209","author":"Hahnefeld","year":"2020","journal-title":"Talanta"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/2\/270\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:10:25Z","timestamp":1760159425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/2\/270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,13]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["cancers13020270"],"URL":"https:\/\/doi.org\/10.3390\/cancers13020270","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,13]]}}}